LTR Pharma (ASX:LTP) prescribed its erectile dysfunction medication Spontan to a first batch of patients under the Australian Therapeutic Goods Administration's (TGA) Authorized Prescriber Scheme, according to a Friday filing with the Australian Securities Exchange.
The scheme will allow specialists to prescribe the nasal spray medication to patients with unmet needs, the pharmaceutical firm said in the filing.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments